| 12 -0.02 (-0.17%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.09  |
1-year : | 20.44 |
| Resists | First : | 14.63 |
Second : | 17.5 |
| Pivot price | 12.01 |
|||
| Supports | First : | 10 |
Second : | 8.31 |
| MAs | MA(5) : | 11.84 |
MA(20) : | 12.2  |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 | Signal : | 0 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 39.1 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 17.5 | Low : | 8.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ELOX ] has closed above bottom band by 49.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 13.05 - 13.13 | 13.13 - 13.21 |
| Low: | 11.03 - 11.1 | 11.1 - 11.18 |
| Close: | 11.85 - 11.99 | 11.99 - 12.13 |
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Tue, 14 Jul 2026
ELOX Price Today: Eloxx Pharmaceuticals, Inc. Stock Price, Quote & Chart - MEXC
Fri, 10 Jul 2026
Price to book forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Thu, 09 Jul 2026
ELOX stock trades on Nasdaq as small-cap biotech focuses on cystic fibrosis therapy - ad-hoc-news.de
Wed, 17 Jun 2026
Coastlands (NASDAQ: ELOX) discloses 410,530 shares, 9.99% stake - Stock Titan
Wed, 10 Jun 2026
symbol__ Stock Quote Price and Forecast - CNN
Tue, 09 Jun 2026
12 Health Care Stocks Moving In Tuesday's Intraday Session - ADITXT INC by Aditxt, Inc. (OTC:ADTX), AIM I - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 302170 (%) |
| Held by Institutions | 26.2 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -16.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -9.17 |
| PEG Ratio | 1.8 |
| Price to Book value | -0.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 7750 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|